Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab in Initially Unresectable Biliary Tract Cancer
NCT04984980Phase 2Unknown
- Sponsor
- Fudan University
- Start
- Aug 2020
- Primary completion
- Jul 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab, bevacizumab in biliary tract cancer (BTC), sponsored by Fudan University. Status: unknown.
02
Drugs
sintilimabbevacizumab
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT04984980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04984980.